Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMP protocol development for personalized adoptive neoantigen-reactive T-cell therapy
NL-OMON47022Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2016
- Countries
- 1
01
Overview
Open-label, single-arm trial in non-small cell lung cancer (NSCLC), bladder cancer, ovarian cancer and 2 more, sponsored by Netherlands Cancer Institute. Primary endpoint: Number and frequency of neoantigen-specific T-cell responses generated. Planned start Sep 2016; status: not yet recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)bladder cancerovarian cancermelanomahead and neck cancer (HNC)
Beyond the preview
Go deeper on NL-OMON47022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47022.